Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Metoclopramide
Drug ID BADD_D01442
Description Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system.[A184934] Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures.[L8417] One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route.[T683] Metoclopramide was initially approved by the FDA in 1980.[A184922]
Indications and Usage Metoclopramide in the oral tablet form is used for symptomatic treatment of both acute and recurrent diabetic gastroparesis, in addition to the treatment of gastroesophageal reflux disease (GERD) in patients who have failed to respond to traditional therapy.[L8414] A nasal spray formulation is also indicated to treat adults with acute, recurrent diabetic gastroparesis.[L14381] In the intravenous injection form, it is indicated for the above conditions as well as for the prevention of vomiting that may follow emetogenic chemotherapy or nausea and vomiting after surgery. Intravenous metoclopramide facilitates intubation of the small bowel and stimulates gastric emptying and barium flow in patients who require radiological examination of the stomach or small intestine. In some cases, the delay of gastrointestinal emptying interferes with the radiographic visualization of the gastrointestinal tract, and metoclopramide is used to facilitate emptying in these cases, allowing for adequate diagnostic visualization.[L8417] Some off-label uses of metoclopramide include the management of radiation-induced nausea and vomiting, gastric bezoars, intractable hiccups, and migraine pain.[A184961,A184964,A184967,A40105]
Marketing Status approved; investigational
ATC Code A03FA01
DrugBank ID DB01233
KEGG ID D00726
MeSH ID D008787
PubChem ID 4168
TTD Drug ID D08VYV
NDC Product Code 49884-689; 51662-1367; 62559-296; 62559-295; 70518-0669; 71335-0362; 71335-0790; 0409-5255; 70518-1193; 71872-7076; 0615-8285; 50090-0132; 63629-2144; 49999-057; 60687-620; 0093-2204; 51079-886; 51079-888; 68788-7226; 51662-1288; 63187-235; 63629-8745; 0409-3414; 68788-7930; 0703-4502; 0093-2203; 51655-240; 55154-4383; 60687-631; 62559-190; 63629-1961; 63629-7967; 42291-596; 63187-404; 0615-7698; 43353-274
UNII L4YEB44I46
Synonyms Metoclopramide | 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide | Metaclopramide | Maxolon | Rimetin | Metoclopramide Hydrochloride | Hydrochloride, Metoclopramide | Metoclopramide Monohydrochloride | Monohydrochloride, Metoclopramide | Metoclopramide Monohydrochloride, Monohydrate | Primperan | Reglan | Cerucal | Metoclopramide Dihydrochloride | Dihydrochloride, Metoclopramide
Chemical Information
Molecular Formula C14H22ClN3O2
CAS Registry Number 364-62-5
SMILES CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Toxic skin eruption12.03.01.073; 23.03.05.003; 10.01.01.0080.000196%Not Available
Metabolic disorder14.11.01.0010.011939%Not Available
Dysgraphia17.02.03.0060.000627%Not Available
Restless legs syndrome17.02.07.008; 15.05.03.0120.007587%Not Available
Cerebral vasoconstriction24.04.06.025; 17.08.02.0120.000294%Not Available
Aortic rupture24.03.04.009; 12.01.11.0070.000490%Not Available
Eye movement disorder17.02.05.025; 06.05.02.0080.000784%Not Available
Mental disorder19.07.01.0020.010488%Not Available
Porphyrin metabolism disorder14.14.01.006; 09.01.10.004; 03.08.01.006--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Parkinson's disease17.01.05.0100.009665%Not Available
Blood disorder01.05.01.004--Not Available
Grimacing17.02.05.029--Not Available
Hyperlipidaemia14.08.03.0010.000196%
Renal impairment20.01.03.010--Not Available
Unevaluable event08.01.03.0510.019938%Not Available
Muscle contracture15.03.05.0240.000294%Not Available
Facial spasm17.04.03.0100.000294%Not Available
Low birth weight baby18.04.02.0030.000392%Not Available
Oral disorder07.05.01.0050.000588%Not Available
Spasmodic dysphonia22.12.03.026; 17.01.03.0070.000294%Not Available
Upper airway obstruction22.12.03.032--Not Available
Oromandibular dystonia17.01.03.0060.000490%Not Available
Kounis syndrome02.02.02.020; 24.04.04.020; 10.01.03.0370.000686%Not Available
Foetal growth restriction18.03.01.0020.000196%
Functional gastrointestinal disorder07.11.01.016--Not Available
Resting tremor17.01.06.0080.001294%Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000784%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000686%
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene